Back to top
more

Calithera Biosciences (CALA)

(Delayed Data from OTC)

$0.01 USD

0.01
775

0.00 (0.00%)

Updated Jul 12, 2024 10:27 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics

Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics

    5 Stocks in Focus on New Analyst Coverage

    Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.

      Surging Earnings Estimates Signal Good News for Calithera Biosciences (CALA)

      Calithera Biosciences (CALA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.

        Earnings Estimates Moving Higher for Calithera Biosciences (CALA): Time to Buy?

        Calithera Biosciences (CALA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.

          Surging Earnings Estimates Signal Good News for Calithera Biosciences (CALA)

          Calithera Biosciences (CALA) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.

            Why Calithera Biosciences (CALA) Could Be Positioned for a Surge

            Calithera Biosciences (CALA) is seeing solid earnings estimate revision, and the stock is showing decent short-term momentum as well.

              Calithera Biosciences (CALA) Jumps: Stock Moves 17% Higher

              Calithera Biosciences, Inc. (CALA) shares rise over 17% in the last trading session.

                Zacks.com featured highlights: Calithera Biosciences, Weibo, Genco Shipping & Trading, Everi Holdings and Willdan Group

                Zacks.com featured highlights: Calithera Biosciences, Weibo, Genco Shipping & Trading, Everi Holdings and Willdan Group

                  Calithera Biosciences (CALA) Rises: Stock Moves Up 19.3%

                  Calithera Biosciences, Inc. (CALA) shares rose over 19% in the last trading session.

                    Incyte and Calithera Enter into Deal for Oncology Candidate

                    Incyte Corporation (INCY) and Calithera Biosciences, Inc. (CALA) entered into a global collaboration and license agreement for research, development and commercialization of Calithera's CB-1158 in hematology and oncology.

                      Is the Options Market Predicting a Spike in Calithera Biosciences (CALA) Stock?

                      Investors in Calithera Biosciences, Inc. (CALA) need to pay close attention to the stock based on moves in the options market lately.

                        Calithera Biosciences (CALA) In Focus: Stock Jumps 46.7%

                        Calithera Biosciences, Inc. (CALA) moved big last session, as its shares jumped almost 47% on the day.

                          Can The Uptrend Continue for Calithera Biosciences (CALA)?

                          Investors certainly have to be happy with Calithera Biosciences, Inc. (CALA) and its short term performance

                            Bristol-Myers, Calithera Team Up for Opdivo/CB-839 Combo

                            Bristol-Myers Squibb Company (BMY) announced a clinical trial collaboration with Calithera Biosciences, Inc. (CALA).